ARCA biopharma
Westminster, US · Delaware corporation · 1 known investors
Oruka is a biopharmaceutical company developing monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory conditions, aiming for high rates of disease clearance with as few as one or two doses per year. Its pipeline includes ORKA-001 and ORKA-002, both in clinical trials for moderate-to-severe plaque psoriasis.
Founders & leadership
MR
Michael R. BristowFounder
TA
Thomas A. KeuerExecutive
BL
Brian L. SelbyinExecutive
PM
Patrick M. WheelerExecutive
CD
Christopher D. OzeroffNamed on SEC filing
Board
DJ
Dan J. MitchellBoard director
JF
Jean-Francois FormelaBoard director
RL
Raymond L. WoosleyBoard director
LS
Linda S. GraisBoard director
RE
Robert E. ConwayBoard director
RB
Richard B. BrewerBoard director
JL
John L. ZabriskieBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$56.5M disclosed across 3 rounds · 2011–2015
▶$51.7MraisedJun 2015 · 14 investors · PharmaceuticalsRule 506(b)
▶$51.7MraisedJun 2015 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher D. OzeroffExecutive Officer
- Thomas A. KeuerExecutive Officer
- Raymond L. WoosleyDirector
- Linda S. GraisDirector
- Dan J. MitchellDirector
- Brian L. SelbyExecutive Officer
- Robert E. ConwayDirector
- Michael R. BristowExecutive Officer, Director
- Offering amount
- $51.7M
- Amount sold
- $51.7M
- Sales commissions
- $2.6M
- Placement agents
- MTS Securities, LLC
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$326.2KraisedFeb 2014 · 2 investors · PharmaceuticalsRule 506(b)
▶$326.2KraisedFeb 2014 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael R. BristowExecutive Officer, Director
- Robert E. ConwayDirector
- Linda S. GraisDirector
- Raymond L. WoosleyDirector
- Christopher D. OzeroffExecutive Officer
- Patrick M. WheelerExecutive Officer
- Offering amount
- $326.2K
- Amount sold
- $326.2K
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedJan 2012 · 6 investors · PharmaceuticalsRule 506(b)
▶$4.5MraisedJan 2012 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael R. BristowExecutive Officer, Director
- Richard B. BrewerDirector
- Jean-Francois FormelaDirector
- Linda GraisDirector
- Patrick M. WheelerExecutive Officer
- John L. ZabriskieDirector
- Burton E. SobelDirector
- Christopher D. OzeroffExecutive Officer
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- Sales commissions
- $97.5K
- Placement agents
- Roth Capital Partners LLC
- First sale
- Dec 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does ARCA biopharma do?
- Oruka is a biopharmaceutical company developing monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory conditions, aiming for high rates of disease clearance with as few as one or two doses per year. Its pipeline includes ORKA-001 and ORKA-002, both in clinical trials for moderate-to-severe plaque psoriasis.
- Who founded ARCA biopharma?
- ARCA biopharma was founded by Michael R. Bristow.
- Who are ARCA biopharma's investors?
- ARCA biopharma's investors include Boulder Ventures.
- How much funding has ARCA biopharma raised?
- ARCA biopharma has disclosed $56.5M raised across 3 rounds.
- Where is ARCA biopharma headquartered?
- ARCA biopharma is headquartered in Westminster, US.